As Cipla approaches its centenary, the company is redefining its strategy by prioritizing innovation to amplify revenues. With ambitions to...

Here’s a thing investors in equity need to keep in mind. A large part of the upmove one might see in the next one or two trading sessions w...

Indian pharma and healthcare firms face a mixed March quarter. While hospitals anticipate steady growth, generic drugmakers grapple with lo...

With the new regulations set by the US FDA, the pathway to creating biosimilars will be both faster and more cost-effective. This developme...

Dr Reddy's Laboratories (DRL) and Intas Pharmaceuticals, both Indian companies, are reportedly in the race to acquire the biosimilar produc...

Under the terms of the agreement, the joint venture will leverage Cipla and Kemwell’s complementary strengths for end-to-end product develo...

"The private market has opened up for vaccination and Dr Reddy’s is likely to benefit from the sale of Sputnik-V vaccine."

Cipla Gulf FZ LCC is expanding its partnership with Alvotech for the marketing and distribution of four biosimilar medicines in Australia a...

Drug firm Cipla will invest around Rand 1.3 billion (over Rs 590 crore) to launch a manufacturing facility in South Africa for the producti...

Drug major Cipla has entered into an agreement to sell its entire stake in Biomab Holding to Biomab Brilliant for a consideration of $25,77...

Hyderabad based Hetero pharma has launched biosimilar drug Rituximab under the brand name of MABALL, used in the treatment of blood cancer.

Actorise is a biosimilar of 'Darbepoetin alfa', which is marketed by US-based Amgen under the brand Aranesp.

A lobby group of biotech drug companies in India has raised concerns about the approval of Cipla's first biosimilar drug Etanercept.

Drug major Cipla said it has launched biosimilar of Etanercept under the brand name 'Etacept' used for treatment of rheumatic disorders in ...

The global pecking order of blockbusters may soon be heading for a major upheaval with biotech drugs toppling the present market leaders.

Drug maker Cipla on Tuesday said it will invest USD 65 million (nearly Rs 300 crore) over the next three years with a Chinese joint venture...

Cipla has terminated its marketing agreement with Avesthagen and is looking at selling its 5.8% stake in the Bangalore-based company.